OR WAIT null SECS
July 19, 2024
With this acquisition, AstraZeneca gets a Phase III therapeutic peptide candidate that adds to the company's rare disease pipeline.
July 18, 2024
Merck gains a late-phase antibody drug candidate for diabetic macular edema and neovascular age-related macular degeneration through its acquisition of EyeBio.
July 17, 2024
Johnson & Johnson gains NM26, a Phase II-ready bispecific antibody in development for atopic dermatitis, boosting its immune-mediated and inflammatory disease portfolio.
July 15, 2024
The acquisition provides Lantheus with worldwide exclusive rights to ß amyloid PET imaging agent, NAV-4694, for its Alzheimer’s disease diagnostic and treatment portfolio.
July 13, 2024
Thermo Fisher will add Olink to its Life Sciences Solutions business.
July 12, 2024
Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.
July 10, 2024
The acquisition of uniQure’s Lexington, Mass., manufacturing operations will boost Genezen’s late-phase and commercial gene therapy development and manufacturing services.
July 04, 2024
The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.
LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.
July 02, 2024
This collaboration aims to support and accelerate clinical development of advanced and novel technologies.